Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion (requires all):~* New diagnosis of AASV (WG or MPA) (within the previous six months)~* Active disease (defined by at least one major or three minor BVAS 2003 items, see appendix 1)~* ANCA positivity (c-ANCA and PR3-ANCA or p-ANCA and MPO-ANCA) or histology confirming active vasculitis from any organ (see appendix )~* Written informed consent~Exclusion Criteria:~* Previous treatment with:~  * MMF: more than two weeks ever.~ * Cyclophosphamide: more than two weeks daily oral or more than 1 pulse of IV CYC (15mg/kg)~ * Rituximab or high dose intravenous immunoglobulin within the last twelve months~* Active infection (including hepatitis B, C, HIV and tuberculosis).~* Known hypersensitivity to MMF, AZA or CYC.~* Cancer or an individual history of cancer (other than resected basal cell skin carcinoma).~* Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception.~* Any condition judged by the investigator that would cause the study to be detrimental to the patient.~* Any other multi-system autoimmune disease including Churg Strauss angiitis, SLE, anti GBM disease and cryoglobulinaemia.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mycophenolate mofetil (Type: EXPERIMENTAL): Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
- cyclophosphamide (Type: ACTIVE_COMPARATOR): pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission

Based on this trial design, predict the completion outcome and termination type (if applicable).